ZA200603085B - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs - Google Patents
4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs Download PDFInfo
- Publication number
- ZA200603085B ZA200603085B ZA200603085A ZA200603085A ZA200603085B ZA 200603085 B ZA200603085 B ZA 200603085B ZA 200603085 A ZA200603085 A ZA 200603085A ZA 200603085 A ZA200603085 A ZA 200603085A ZA 200603085 B ZA200603085 B ZA 200603085B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- compound
- methoxy
- phenoxy
- acetic acid
- Prior art date
Links
- 125000005359 phenoxyalkyl group Chemical group 0.000 title description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 122
- 150000001875 compounds Chemical class 0.000 claims description 116
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 106
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 99
- 229910052801 chlorine Inorganic materials 0.000 claims description 91
- 229910052731 fluorine Inorganic materials 0.000 claims description 75
- 229910052739 hydrogen Inorganic materials 0.000 claims description 59
- -1 cyano, hydroxy, acetyl Chemical group 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 29
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 11
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000004789 chlorodifluoromethoxy group Chemical group ClC(O*)(F)F 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 125000004788 dichlorofluoromethoxy group Chemical group ClC(O*)(F)Cl 0.000 claims description 3
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- DZFXGWSEUWQQLY-UHFFFAOYSA-N 2-[2-methyl-4-[4-[4-(trifluoromethyl)phenyl]but-3-enylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCCC=CC=2C=CC(=CC=2)C(F)(F)F)=C1 DZFXGWSEUWQQLY-UHFFFAOYSA-N 0.000 claims description 2
- MYJXROCQWAHVTL-UHFFFAOYSA-N 2-[4-[2-ethoxy-4-[4-(trifluoromethyl)phenyl]butyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C(C)=CC=1SCC(OCC)CCC1=CC=C(C(F)(F)F)C=C1 MYJXROCQWAHVTL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 claims description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- LQVHUYPVFFYRCC-OAHLLOKOSA-N 2-[2-methyl-4-[(2r)-2-[[4-(trifluoromethoxy)phenoxy]methyl]butyl]sulfanylphenyl]sulfanylacetic acid Chemical compound C([C@@H](CC)CSC=1C=C(C)C(SCC(O)=O)=CC=1)OC1=CC=C(OC(F)(F)F)C=C1 LQVHUYPVFFYRCC-OAHLLOKOSA-N 0.000 claims 1
- HHWAGXNCYPIKHF-GOSISDBHSA-N 2-[4-[(2r)-2-[(4-tert-butylphenoxy)methyl]butyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](CC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(C)(C)C)C=C1 HHWAGXNCYPIKHF-GOSISDBHSA-N 0.000 claims 1
- WKLRGLINPLQQRP-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethoxy)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(OC(F)(F)F)C=C1 WKLRGLINPLQQRP-QGZVFWFLSA-N 0.000 claims 1
- GGXVDDSJTPSVOS-HXUWFJFHSA-N 2-[4-[(2r)-3-(4-tert-butylphenoxy)-2-ethoxypropyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(C)(C)C)C=C1 GGXVDDSJTPSVOS-HXUWFJFHSA-N 0.000 claims 1
- UDVUZTGMCLBNGK-UHFFFAOYSA-N 2-[4-[2,4-diethoxy-4-[4-(trifluoromethyl)phenyl]butyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(OCC)CC(OCC)CSC1=CC=C(OCC(O)=O)C(C)=C1 UDVUZTGMCLBNGK-UHFFFAOYSA-N 0.000 claims 1
- WMDITBUCSIRSPY-UHFFFAOYSA-N 2-[4-[2-(ethoxymethyl)-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C(C)=CC=1SCC(COCC)COC1=CC=C(C(F)(F)F)C=C1 WMDITBUCSIRSPY-UHFFFAOYSA-N 0.000 claims 1
- YUWKUOSZJYOUHQ-UHFFFAOYSA-N 2-[4-[2-[[4-(trifluoromethyl)phenoxy]methyl]butylsulfanyl]phenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C=CC=1SCC(CC)COC1=CC=C(C(F)(F)F)C=C1 YUWKUOSZJYOUHQ-UHFFFAOYSA-N 0.000 claims 1
- WNMOQSOJZRJGJT-UHFFFAOYSA-N 2-[4-[4-methoxy-2-[[4-(trifluoromethyl)phenoxy]methyl]butyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C(C)=CC=1SCC(CCOC)COC1=CC=C(C(F)(F)F)C=C1 WNMOQSOJZRJGJT-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 108010023302 HDL Cholesterol Proteins 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 108010015181 PPAR delta Proteins 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 206010068961 Hypo HDL cholesterolaemia Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 101150014691 PPARA gene Proteins 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical group C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- ULCXVOCPRAZKAJ-OAHLLOKOSA-N 2-[2-methyl-4-[(2r)-2-[[4-(trifluoromethoxy)phenoxy]methyl]butyl]sulfanylphenoxy]acetic acid Chemical compound C([C@@H](CC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(OC(F)(F)F)C=C1 ULCXVOCPRAZKAJ-OAHLLOKOSA-N 0.000 description 1
- KSCZMOSACZKJJW-UHFFFAOYSA-N 2-[2-methyl-4-[2-[[4-(trifluoromethyl)phenoxy]methyl]butylsulfanyl]phenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C(C)=CC=1SCC(CC)COC1=CC=C(C(F)(F)F)C=C1 KSCZMOSACZKJJW-UHFFFAOYSA-N 0.000 description 1
- XTTUYORRJQNRLF-UHFFFAOYSA-N 2-[2-methyl-4-[3-[4-(trifluoromethyl)phenoxy]propylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCCCOC=2C=CC(=CC=2)C(F)(F)F)=C1 XTTUYORRJQNRLF-UHFFFAOYSA-N 0.000 description 1
- UIZWCLWHYGIZAM-UHFFFAOYSA-N 2-[3-chloro-4-[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanylphenyl]acetic acid Chemical compound C=1C=C(CC(O)=O)C=C(Cl)C=1SCC(OCC)COC1=CC=C(C(F)(F)F)C=C1 UIZWCLWHYGIZAM-UHFFFAOYSA-N 0.000 description 1
- CHEFOCUEUMWPNL-UHFFFAOYSA-N 2-[4-[2-(cyanomethyl)-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC(COC=2C=CC(=CC=2)C(F)(F)F)CC#N)=C1 CHEFOCUEUMWPNL-UHFFFAOYSA-N 0.000 description 1
- OBIYGPHKYVDIDL-UHFFFAOYSA-N 2-[4-[4-ethoxy-2-[[4-(trifluoromethyl)phenoxy]methyl]butyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C=1C=C(OCC(O)=O)C(C)=CC=1SCC(CCOCC)COC1=CC=C(C(F)(F)F)C=C1 OBIYGPHKYVDIDL-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical class C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 229940063720 lopid Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940055755 tricor Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50414603P | 2003-09-19 | 2003-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200603085B true ZA200603085B (en) | 2007-09-26 |
Family
ID=34549183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200603085A ZA200603085B (en) | 2003-09-19 | 2006-04-18 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Country Status (30)
Country | Link |
---|---|
US (9) | US7301050B2 (el) |
EP (2) | EP1667964B1 (el) |
JP (1) | JP4928941B2 (el) |
KR (1) | KR101111475B1 (el) |
CN (1) | CN1882533B (el) |
AR (1) | AR045773A1 (el) |
AT (1) | ATE542793T1 (el) |
AU (1) | AU2004285849B2 (el) |
BR (1) | BRPI0414268B8 (el) |
CA (1) | CA2539446C (el) |
CO (1) | CO5680476A2 (el) |
CR (1) | CR8301A (el) |
CY (1) | CY1110555T1 (el) |
DE (1) | DE602004022179D1 (el) |
DK (1) | DK1667964T3 (el) |
EA (1) | EA012241B1 (el) |
EC (1) | ECSP066434A (el) |
ES (2) | ES2378435T3 (el) |
HK (2) | HK1092784A1 (el) |
IL (1) | IL174398A (el) |
NO (2) | NO338511B1 (el) |
NZ (1) | NZ545943A (el) |
PL (1) | PL1667964T3 (el) |
PT (1) | PT1667964E (el) |
SG (1) | SG145752A1 (el) |
SI (1) | SI1667964T1 (el) |
TW (1) | TWI336238B (el) |
UA (1) | UA87467C2 (el) |
WO (1) | WO2005042478A2 (el) |
ZA (1) | ZA200603085B (el) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1670744B9 (en) * | 2003-09-19 | 2012-09-05 | Janssen Pharmaceutica NV | 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs |
ATE542793T1 (de) | 2003-09-19 | 2012-02-15 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga |
MY145712A (en) * | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
UY30288A1 (es) * | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
MX2011004077A (es) * | 2008-10-17 | 2011-08-17 | Metabolex Inc | Metodos para reducir particulas de ldl densas, pequeñas. |
CN104487542B (zh) * | 2012-07-06 | 2016-10-12 | 默克专利股份有限公司 | 双介晶化合物和介晶介质 |
EA201691039A1 (ru) | 2013-11-20 | 2016-11-30 | Саймабэй Терапьютикс, Инк. | Лечение гомозиготной семейной гиперхолестеринемии |
US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
PL3119384T3 (pl) | 2014-03-20 | 2019-03-29 | Cymabay Therapeutics, Inc. | Leczenie wewnątrzwątrobowych chorób cholestatycznych |
DK3129018T3 (da) | 2014-04-11 | 2020-01-20 | Cymabay Therapeutics Inc | Behandling af NAFLD og NASH |
MX2016017081A (es) | 2014-06-26 | 2017-05-01 | Cymabay Therapeutics Inc | Tratamiento de hipertrigliceridemia grave. |
US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
US20200276178A1 (en) | 2017-09-13 | 2020-09-03 | Novartis Ag | Combinations comprising fxr agonists |
EP3973959A1 (en) | 2017-09-26 | 2022-03-30 | CymaBay Therapeutics, Inc. | Treatment of cholestatic pruritus with seladelpar |
US10702488B2 (en) * | 2017-12-19 | 2020-07-07 | Theriac Biomedical Inc. | PPAR-γ activators, HDAC inhibitors and their therapeutical usages |
US11497723B1 (en) * | 2017-12-19 | 2022-11-15 | Tony Antakly | PPAR-gamma activators, HDAC inhibitors and their therapeutical usages |
EA202191379A1 (ru) | 2018-11-16 | 2021-08-06 | Саймабэй Терапьютикс, Инк. | Комбинированное лечение nafld и nash |
EP3880187A1 (en) | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Treatment of obesity and its complications |
WO2021097027A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of alcoholic liver disease |
WO2021097034A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
CN112824380A (zh) * | 2019-11-21 | 2021-05-21 | 杭州百诚医药科技股份有限公司 | α-氟代查耳酮类衍生物及其应用 |
LT4225291T (lt) | 2021-02-01 | 2024-06-10 | Cymabay Therapeutics, Inc. | Cholangiopatijų gydymas seladelparu |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517051A (en) * | 1964-03-20 | 1970-06-23 | Merck & Co Inc | Phenoxy substituted phenylacetic acids |
DE2460689C3 (de) * | 1974-12-20 | 1980-06-26 | Klinge Pharma Gmbh & Co, 8000 Muenchen | 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US4109013A (en) * | 1974-12-20 | 1978-08-22 | Klinge Pharma Gmbh & Co. | Substituted propanol-(2) derivatives of hydroxamic acids and the use thereof as hypolipemic drugs |
US4125732A (en) | 1977-05-06 | 1978-11-14 | American Cyanamid Company | 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters |
DE3026924A1 (de) | 1980-07-16 | 1982-02-18 | Klinge Pharma GmbH & Co, 8000 München | 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE3028776A1 (de) | 1980-07-29 | 1982-02-25 | Klinge Pharma GmbH & Co, 8000 München | Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE3169761D1 (en) * | 1981-01-09 | 1985-05-09 | Fisons Plc | Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them |
JPS58177934A (ja) * | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
ATE22072T1 (de) | 1982-09-30 | 1986-09-15 | Merck Frosst Canada Inc | Leukotrienantagonisten, deren herstellung und diese enthaltende zusammensetzungen. |
US4820867A (en) * | 1983-04-21 | 1989-04-11 | Merck Frosst Canada, Inc. | Phenoxypropoxy halophenylacetic acids as leukotriene antagonists |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
JPS61268651A (ja) * | 1985-05-23 | 1986-11-28 | Takeda Chem Ind Ltd | フエニル酢酸誘導体およびその製造法 |
EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH0714910B2 (ja) | 1988-12-13 | 1995-02-22 | 塩野義製薬株式会社 | 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤 |
US5487008A (en) | 1990-04-20 | 1996-01-23 | The Regents Of The University Of Michigan | Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain |
EP0562796A1 (en) | 1992-03-23 | 1993-09-29 | Terumo Kabushiki Kaisha | Phenoxyacetic acid compounds and medical preparations containing them |
US5726165A (en) * | 1994-07-29 | 1998-03-10 | Smithkline Beecham P.L.C. | Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor |
DE69733154T2 (de) * | 1996-02-02 | 2006-03-09 | Merck & Co., Inc. | Verfahren zur behandlung von diabetes und verwandter krankheitszustände. |
CA2245529A1 (en) | 1996-02-02 | 1997-08-07 | Soumya P. Sahoo | Antidiabetic agents |
JP3268242B2 (ja) | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
WO1999004815A1 (fr) | 1997-07-24 | 1999-02-04 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales hypocholesterolemiantes |
ES2281146T3 (es) | 1997-12-19 | 2007-09-16 | MERCK & CO., INC. | Ariltiazolidindionas utiles como compuestos terapeuticos. |
CN1348439A (zh) | 1999-04-20 | 2002-05-08 | 诺沃挪第克公司 | 新化合物及其制备和用途 |
CA2376919C (en) * | 1999-06-18 | 2008-11-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
GB0003310D0 (en) * | 2000-02-15 | 2000-04-05 | Univ Sheffield | Bone formation |
GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
SK14912003A3 (sk) | 2001-06-07 | 2004-09-08 | Eli Lilly And Company | Modulátory receptorov aktivovaných peroxizomálnymi proliferátormi (PPAR) |
EP1414778A1 (en) * | 2001-07-30 | 2004-05-06 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
BRPI0211844B8 (pt) | 2001-08-10 | 2021-05-25 | Nippon Chemiphar Co | composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica |
JP4276074B2 (ja) | 2001-10-12 | 2009-06-10 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
ITRM20020014A1 (it) | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
AU2003224632A1 (en) | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Hppars activators |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
BR0314335A (pt) | 2002-09-05 | 2005-07-26 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade |
BR0315667A (pt) | 2002-10-28 | 2005-09-06 | Novo Nordisk As | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento |
PL376718A1 (pl) | 2002-10-28 | 2006-01-09 | Novo Nordisk A/S | Nowe związki, ich wytwarzanie i stosowanie |
ES2384973T3 (es) | 2003-02-14 | 2012-07-16 | Biogen Idec Ma Inc. | Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas |
US20060257987A1 (en) * | 2003-08-20 | 2006-11-16 | Gonzalez Valcarcel Isabel Cris | Ppar modulators |
EP1670744B9 (en) * | 2003-09-19 | 2012-09-05 | Janssen Pharmaceutica NV | 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs |
ATE542793T1 (de) * | 2003-09-19 | 2012-02-15 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga |
BRPI0416106A (pt) | 2003-10-31 | 2007-01-02 | Janssen Pharmaceutica Nv | ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos |
EP1745047B1 (en) | 2004-04-21 | 2010-03-24 | Schering Corporation | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists |
CA2571722C (en) | 2004-07-01 | 2012-12-11 | F. Hoffmann-La Roche Ag | Phenyl derivatives comprising an acetylene group |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
MY145712A (en) | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
GB0618963D0 (en) | 2006-09-26 | 2006-11-08 | Ucl Business Plc | Formulations and composites with reactive fillers |
-
2004
- 2004-09-16 AT AT09075188T patent/ATE542793T1/de active
- 2004-09-16 UA UAA200603107A patent/UA87467C2/ru unknown
- 2004-09-16 EP EP04816875A patent/EP1667964B1/en active Active
- 2004-09-16 CA CA2539446A patent/CA2539446C/en active Active
- 2004-09-16 SI SI200431248T patent/SI1667964T1/sl unknown
- 2004-09-16 DE DE602004022179T patent/DE602004022179D1/de active Active
- 2004-09-16 ES ES09075188T patent/ES2378435T3/es active Active
- 2004-09-16 BR BRPI0414268A patent/BRPI0414268B8/pt active IP Right Grant
- 2004-09-16 CN CN2004800335902A patent/CN1882533B/zh active Active
- 2004-09-16 EP EP09075188A patent/EP2100877B1/en active Active
- 2004-09-16 EA EA200600440A patent/EA012241B1/ru unknown
- 2004-09-16 KR KR1020067007358A patent/KR101111475B1/ko active IP Right Grant
- 2004-09-16 PT PT04816875T patent/PT1667964E/pt unknown
- 2004-09-16 WO PCT/US2004/030375 patent/WO2005042478A2/en active Application Filing
- 2004-09-16 PL PL04816875T patent/PL1667964T3/pl unknown
- 2004-09-16 US US10/942,478 patent/US7301050B2/en active Active
- 2004-09-16 JP JP2006527026A patent/JP4928941B2/ja active Active
- 2004-09-16 DK DK04816875T patent/DK1667964T3/da active
- 2004-09-16 ES ES04816875T patent/ES2328581T3/es active Active
- 2004-09-16 AU AU2004285849A patent/AU2004285849B2/en active Active
- 2004-09-16 NZ NZ545943A patent/NZ545943A/en unknown
- 2004-09-16 SG SG200806114-5A patent/SG145752A1/en unknown
- 2004-09-17 TW TW093128361A patent/TWI336238B/zh active
- 2004-09-20 AR ARP040103376A patent/AR045773A1/es active IP Right Grant
-
2006
- 2006-03-17 EC EC2006006434A patent/ECSP066434A/es unknown
- 2006-03-17 CR CR8301A patent/CR8301A/es not_active Application Discontinuation
- 2006-03-19 IL IL174398A patent/IL174398A/en active IP Right Grant
- 2006-03-30 CO CO06031466A patent/CO5680476A2/es active IP Right Grant
- 2006-04-18 ZA ZA200603085A patent/ZA200603085B/en unknown
- 2006-04-19 NO NO20061728A patent/NO338511B1/no unknown
- 2006-12-11 HK HK06113590.1A patent/HK1092784A1/xx unknown
-
2007
- 2007-10-15 US US11/872,417 patent/US7635718B2/en active Active
-
2009
- 2009-10-20 CY CY20091101087T patent/CY1110555T1/el unknown
- 2009-11-23 US US12/623,824 patent/US8106095B2/en active Active
-
2010
- 2010-03-15 HK HK10102665.8A patent/HK1137737A1/xx unknown
-
2011
- 2011-12-21 US US13/332,453 patent/US8518997B2/en active Active
-
2013
- 2013-08-14 US US13/966,493 patent/US20130331453A1/en not_active Abandoned
-
2015
- 2015-04-15 NO NO20150447A patent/NO341448B1/no unknown
-
2016
- 2016-03-18 US US15/074,125 patent/US9724322B2/en active Active
-
2017
- 2017-07-10 US US15/644,993 patent/US20170304254A1/en not_active Abandoned
-
2019
- 2019-03-05 US US16/292,406 patent/US20190192475A1/en not_active Abandoned
-
2023
- 2023-03-13 US US18/120,484 patent/US20230210808A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200603085B (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | |
ZA200603084B (en) | 4-[(phenoxyalkyl)thio]-phenoxyacetic acids and analogs | |
ES2561422T3 (es) | Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos | |
ZA200604420B (en) | Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (PPAR) dual agonists | |
CA2580491C (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives and use thereof as ppar modulators | |
CA2858285C (en) | 1,3-diphenylpropane derivatives, preparations and uses thereof | |
MXPA06003180A (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |